ANKMJ
Ankyra Medical Journal

Ankyra Medical Journal (AnkMJ), formerly known as the Journal of Translational and Practical Medicine, regularly publishes international quality issues in the field of Medicine in the light of current information.

eISSN: 3023-655X
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Case Report
The effect of sodium-glucose linked transporter 2 inhibitor and glucagon-like peptide-1 receptor agonist on weight and blood pressure control in an obese diabetic patient: a case report
Abstract
Obesity and diabetes are two closely related and often co-occurring clinical conditions that are difficult to treat and full of uncertainties. Moreover, they are often accompanied by another disease that is just as difficult to treat: hypertension. Although the picture may seem complex, pessimistic, and requiring a lot of medication, it is possible to develop a holistic strategy. With the case we have presented, we would like to share our treatment plan focused on the treatment of diabetes and its results and draw attention to the effects of antidiabetic therapies on weight loss and blood pressure control.

Keywords : Sodium-glucose linked transporter 2 inhibitor, SGLT2-i, glucagon-like peptide-1 receptor agonist, GLP-1RA, type 2 diabetes, hypertension

Download Article


1. Jobe M, Mactaggart I, Bell S, et al. Prevalence of hypertension, diabetes, obesity, multimorbidity, and related risk factors among adult Gambians: a cross-sectional nationwide study. <em>The Lancet Global Health</em>. 2024;12(1): e55-e65.
2. Ma H, Lin Y-H, Dai L-Z, Lin C-S, Huang Y, Liu S-Y. Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis. <em>BMJ Open</em>. 2023;13(3):e061807.
3. Shariq OA, McKenzie TJ. Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery. <em>Gland Surgery</em>. 2020;9(1):80.
4. Diallo A, Carlos-Bolumbu M, Galtier F. Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis. <em>Acta Diabetologica</em>. 2023;60(12):1651-1662.
5. Varlibaş A, &Ccedil;ifci A. Management of patients with diabetes and chronic renal disease: management of patients with diabetic and chronic kidney disease. <em>J Translational Practical Med</em> 2022;1(1):14-22.
6. Salvatore T, Galiero R, Caturano A, et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. <em>Int J Mol Sci</em>. 2022;23(7):3651.
7. Tan B, &Ccedil;ifci A. The relationship between sodium glucose co-transporter 2 inhibitors and diabetic ketosis/infection: single center retrospective experiences. <em>Ankyra Med J</em>. 2024;3(1):1-5.
8. Goud A, Zhong J, Peters M, Brook RD, Rajagopalan S. GLP-1 agonists and blood pressure: a review of the evidence. <em>Curr Hypertens Rep. </em>2016;18(2):16<em>.</em>
9. Sivertsen J, Rosenmeier J, Holst JJ, Vilsb&oslash;ll T. The effect of glucagon-like peptide 1 on cardiovascular risk. <em>Nat Rev Cardiol.</em> 2012;9(4):209-222.
10. Gourdy P, Darmon P, Dievart F, Halimi J-M, Guerci B. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). <em>Cardiovas Diabetol.</em> 2023;22(1):79.
Article available in :
Volume 3, Issue 6, 2024
Page : 146-148
https://doi.org/10.51271/ANKMJ-0033
Article Information
Received : 03 Eyl 2024
Accepted : 25 Eyl 2024
Published : 13 Kas 2024
Corresponding Author :

Artuner Varlıbaş: Department of Internal Medicine, Faculty of Medicine, Kırıkkale University, Kırıkkale, Turkiye

[email protected]
Citation : Haktanıyan ZN, Varlıbaş A, Çifci A. The effect of SGLT2-I and GLP-1 RA on weight and blood pressure control in an obese diabetic patient: a case report. Ank Med J. 2024;3(6):146-148.

Read: 83
Cited: 0
Download : 43
_Footer